Clinical research company IQVIA (NYSE: IQV) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 8.4% year on year to $4.15 billion. The company expects the full year’s revenue to be around $17.25 billion, close to analysts’ estimates. Its non-GAAP profit of $2.90 per share was 2.9% above analysts’ consensus estimates.

Is now the time to buy IQV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

IQVIA’s first quarter results were positively received by the market, reflecting stronger-than-expected revenue growth and solid execution in both its Commercial and R&D Solutions segments. Management attributed this outperformance to increased client demand across core offerings, particularly in areas integrating artificial intelligence and analytics. CEO Ari Bousbib highlighted that, “our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled,” compared to a year ago, with notable momentum in Patient Solutions and Analytics and Consulting. The company’s ability to secure large, multiyear contracts with leading pharmaceutical clients and to embed AI across business lines were key factors supporting robust top and bottom line performance.

Looking forward, IQVIA’s updated guidance is based on expectations of continued demand for its AI-enabled platforms and growing pipelines in both Commercial and R&D Solutions. Bousbib noted that client conversations increasingly focus on expanding the use of AI to accelerate product launches and improve operational efficiency, stating, “Large pharma clients tell us they plan to increase the number of molecules in their pipeline because they are using AI to identify more targets.” Management emphasized that a strong backlog and growing qualified pipeline support their outlook, while productivity initiatives are expected to help offset margin headwinds from currency fluctuations and business mix. The company remains focused on scaling its AI agent deployment and capitalizing on renewed industry investment in drug development.

Key Insights from Management’s Remarks

Management pointed to accelerating customer adoption of AI-powered offerings, a surge in client pipeline activity, and improved performance across both major business lines as the primary drivers of the quarter’s results.

• AI integration accelerates demand: IQVIA has embedded AI into both its Commercial and R&D Solutions, with 192 AI agents deployed covering 64 use cases. Nineteen of the top twenty pharmaceutical companies are already using these AI agents, which management credits for driving new business and deepening client relationships.
• Commercial Solutions growth: The Commercial Solutions segment saw its organic revenue growth rate double year over year, propelled by increased activity in Patient Solutions, Analytics and Consulting, and Commercial Engagement Services. Notably, the Analytics and Consulting division experienced its highest growth in three years.
• Large contract wins: IQVIA secured multiyear agreements with major pharmaceutical clients—including Pfizer and Boehringer Ingelheim—to provide AI-enabled data platforms and commercial support across dozens of countries. These deals are expected to support future product launches and broader market access.
• R&D Solutions bookings mix: The R&D Solutions segment delivered strong bookings growth, but management noted that a lower proportion of pass-through bookings (which have no profit impact) affected certain reported metrics. The mix shift toward more full-service contracts was described as a one-off, not a trend.
• Industry tailwinds and backlog: Management pointed to a record $34.2 billion backlog and mid single-digit growth in the qualified sales pipeline. Rising trial complexity, increased outsourcing, and renewed biotech funding are seen as supportive of sustained demand in both core segments.

Drivers of Future Performance

IQVIA’s outlook for the coming quarters centers on scaling AI adoption, expanding large client relationships, and managing ongoing margin pressures from mix and currency.

• AI-driven service expansion: Management expects continued growth as more clients adopt IQVIA’s AI-powered platforms to accelerate drug discovery, optimize trial design, and streamline commercial operations. The company believes this technology integration will create additional demand for both new and existing services.
• Pipeline and backlog conversion: A record backlog and strong qualified pipeline are expected to drive revenue growth, with large pharma clients planning to expand their pipelines and outsource more development. Management highlighted that new drug launches and ongoing collaborations with industry leaders should support sustained top-line momentum.
• Margin management focus: While productivity programs are expected to offset some pressures, management acknowledged that foreign currency fluctuations and periodic changes in business mix could challenge reported margins. The company intends to maintain operational discipline and prioritize margin stability as it invests in technology and service capabilities.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will be watching (1) how quickly IQVIA’s AI solutions gain traction across key pharma clients, (2) the pace at which large contracts and backlog convert into realized revenue, and (3) the company’s ability to manage margin pressures from currency and business mix. Ongoing developments in biotech funding and client R&D pipelines will also be important indicators of future performance.

IQVIA currently trades at $174.75, up from $160.94 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.